Last reviewed · How we verify
Metholone (drostanolone propionate)
Metholone (generic name: drostanolone propionate) is a drostanolone propionate drug developed by Eli Lilly. It is currently FDA-approved for Malignant neoplasm of breast.
At a glance
| Generic name | drostanolone propionate |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | drostanolone propionate |
| Target | Androgen receptor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant neoplasm of breast
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metholone CI brief — competitive landscape report
- Metholone updates RSS · CI watch RSS
- Eli Lilly portfolio CI
Frequently asked questions about Metholone
What is Metholone?
Metholone (drostanolone propionate) is a drostanolone propionate drug developed by Eli Lilly, indicated for Malignant neoplasm of breast.
What is Metholone used for?
Metholone is indicated for Malignant neoplasm of breast.
Who makes Metholone?
Metholone is developed and marketed by Eli Lilly (see full Eli Lilly pipeline at /company/eli-lilly).
What is the generic name of Metholone?
drostanolone propionate is the generic (nonproprietary) name of Metholone.
What drug class is Metholone in?
Metholone belongs to the drostanolone propionate class. See all drostanolone propionate drugs at /class/drostanolone-propionate.
What development phase is Metholone in?
Metholone is FDA-approved (marketed).
What does Metholone target?
Metholone targets Androgen receptor and is a drostanolone propionate.
Related
- Drug class: All drostanolone propionate drugs
- Target: All drugs targeting Androgen receptor
- Manufacturer: Eli Lilly — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Malignant neoplasm of breast
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing